MOGRIFY

Mogrify® is a UK biopharmacetuical company whose mission is to transform the development of ex vivo cell therapies, as well as pioneer a new class of in vivo reprogramming therapies. The Company has developed a proprietary direct cellular reprogramming platform that, for the first time, makes it possible to both systematically enhance the efficiency of stem cell-derived reprogramming and directly convert (transdifferentiate) mature cell types into other mature cell types (or states) without go... ing through a pluripotent stem cell- or progenitor cell-state. Mogrify is applying its proprietary and award-winning platforms to generate the scalable source of functional cell types required to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies for indications of high unmet clinical need in immuno-oncology, ophthalmology and other disease areas. The platform is protected by the foundational patent application and a suite of additional patent applications covering improvements and extensions to the core platform and specific cell conversions. Uniquely positioned to address a regenerative medicine market estimated to be worth $39 billion USD by 2023, the Company is commercializing this via a business model of internal cell therapy development, co-development partnerships, as well as the exploration and generation of novel cell-based and in vivo reprogramming therapies for broad therapeutic application. Mogrify was founded in 2016 and is headquartered in Cambridge, United Kingdom.More